Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Last news posted on their website is from 2017. They appear to specialize in manufacturing of these types of tests based upon their site and infectious disease section.
A company can not operate on false pretenses for this long nor be able to ramp up that much product this quickly if not legitimate IMO. Expect to see a very quick response from Predictive.
Mmm.. glad I bought some M-43. Going to be a good Monday.
There are two checks: IgG and IgM. One tests for current infected, one tests for past/immunity.
Only thing I'm worried about is how low my beer fridge is running. Going to be a fun show to watch.
Long-term this shake may be a good thing as we get rid of toxic holdings.
C'mon, Rain. That suit is bullshit.
Someone already catch this? Per https://predictivelabs.com/wp-content/uploads/2020/03/Assurance-AB-Point-of-Care-Instructions-for-Use.pdf ...
While I also hope there is a Thermo relation, there is no identification that others are utilizing so far.
Probably the closest I've found: https://www.biospace.com/article/releases/20-20-bioresponse-to-launch-rapid-coronavirus-test-kits-in-u-s-following-green-light-from-fda/
Good to see, hope it brings more attention to PRED, but they appear to be just acting in a manufacturing/distribution capacity along with many others with the same test.
Glad to see they're stepping in to support regardless of share price impact!
Agree, clear cut case on unclear cuts.
You can also identify perma-shorts by the ludicrous logic they try to continually string together.
Agree... will be zero impact from coronavirus on PRED. Even if there was, not a major financial benefit and would be a waste of resources.
But, good to know stem cells are gaining more positive light.. will be good for when/if the products are sold off.
Sounds great to me. I'll bring some buffalo dip.
Previously he stated he called the main office, which the Katy office surely is not. Also speaking to a receptionist alone doesn't seem to be DD I would hold to.
I will also send a general contact email so we can have someone with actual information advise. Overall a waste of time though, as no chance a clinic like HFI would allow any false news in a release like this.
Yes, everyone move along. Nothing to see here.
If a material event did happen mid-to-late last week, I would imagine PRED would take the full 4 business days to get the public release drafted right.
You're right for once. Only a blind person would see those photos and think they're fake.
Can confirm. Sacrificed a goat last weekend with Brad.
Without proof, citations, etc. Yes, the definition of fair and informed. Don't care if you're long or short, everyone should be held to the same standard for claims.
I just called everyone that works for the company, all have been paid on time
Wow, this is easy.
Mike Dey, Dr. Rabin, Christine Seward, ...
Name a few penny stocks you like. I'll go and pay for a couple promos on them so you'll have to sell by your logic.
Realize that there are many parties who may want the promo... both longs and shorts. Promos are absolutely manipulation, but associating them to a company's legitimacy is downright absurd given anyone with any position can authorize one to take advantage of stocks with the right volume/volatility.
Ding ding ding.
Artguide Beta Site Highlights:
• 892 women tested with ARTguide since March 2019
• Outcomes data available on first 175 treatment cycles after ARTguide test
• 70 ongoing pregnancies- 650% greater success with low endometriosis gene burden (p<0.001)
I'm fairness, that study was done respective to salary (to which there is also a correlation to time invested and likely stress). I would think the outcome would be very different in that scenario to one of large investment gain.
We have all had a few years now to course correct our spending dreams, which spending regret also plays a large part in windfall gain unhappiness.
So what I'm saying is... that new Corvette will be just what I need. Lol
I would have to believe that there's next to no chance we see one. They have a good share structure now, and it wouldn't take much to move it to $2.
There's also a significant perception issue with a R/S as most companies use it to save themselves from being booted off an exchange. Just too many negative connotations to entertain.
Talk about ridiculous.
Great summary of many of our thoughts.
Someone's awful grumpy, ChanTimlyLacy
Gonegadin, autocorrect put him on time-out.
But yeah, hope nothing illness related.
This seems like the most plausible reasoning and intent of the letter. Very likely he was concerned about the continued investment into the diagnostics and the red on the quarterly reports.
I would very much agree with the board's ultimate position.
A finance director has concerns over viability of scientific data, and disagrees with industry leading experts and veterans.
Hmm. Why should we be concerned? Lol
Guess Sorrentino, Dey, and Taylor must be boneheads in addition to Thermofisher.
8K published on Moyes departure. Least concerning board member to lose IMO (serial OTC board member). Expect a new replacement shortly, but majority is still maintained and also clears up unfounded rumors of other departures.
https://www.sec.gov/Archives/edgar/data/1382943/000109181820000003/pred01072020form8k.htm
1.26 or bust.
Lol
If only we had more funds. Going to be one hell of a new year.
Method of testing for endometriosis and treatment therefor
Patent number: 9434991
Abstract: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.
Type: Grant
Filed: March 7, 2013
Date of Patent: September 6, 2016
Assignee: Juneau Biosciences, LLC.
Inventors: Kenneth Ward, Rakesh N. Chettier, Hans Albertsen
Method of Testing for Endometriosis and Treatment Therefor
Publication number: 20180245156
Abstract: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.
Type: Application
Filed: December 11, 2017
Publication date: August 30, 2018
Applicant: Juneau Biosciences, LLC
Inventors: Kenneth Ward, Rakesh N. Chettier, Hans Albertsen
Method of Testing for Endometriosis and Treatment Therefor
Publication number: 20160367568
Abstract: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.
Type: Application
Filed: September 5, 2016
Publication date: December 22, 2016
Applicant: Juneau Biosciences, LLC
Inventors: Kenneth Ward, Rakesh N. Chettier, Hans M. Albertsen
Method of Testing for Endometriosis and Treatment Therefor
Publication number: 20150368714
Abstract: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.
Type: Application
Filed: March 7, 2013
Publication date: December 24, 2015
Applicant: JUNEAU BIOSCIENCES, LLC
Inventors: Kenneth Ward, Rakesh N. Chettier, Hans Albertsen
Method of Determining Predisposition to Endometriosis
Publication number: 20150363558
Abstract: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.
Type: Application
Filed: September 4, 2012
Publication date: December 17, 2015
Applicant: JUNEAU BIOSCIENCES, LLC
Inventors: Kenneth Ward, Pamela Farrington, Rakesh N. Chettier, Hans Albertsen
Genetic Markers Associated with Endometriosis and Use Thereof
Publication number: 20150361494
Abstract: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.
Type: Application
Filed: June 13, 2011
Publication date: December 17, 2015
Applicant: JUNEAU BIOSCIENCES, LLC
Inventors: Kenneth Ward, Hans Albertson, Georges C. Frech, Rakesh N. Chettier
Method of Testing for Endometriosis and Treatment Therefor
Publication number: 20150133382
Abstract: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.
Type: Application
Filed: January 12, 2015
Publication date: May 14, 2015
Applicant: JUNEAU BIOSCIENCES, LLC
Inventors: Kenneth Ward, Rakesh N. Chettier, Hans Albertsen
Method of testing for endometriosis and treatment therefor
Patent number: 8932993
Abstract: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.
Type: Grant
Filed: March 7, 2013
Date of Patent: January 13, 2015
Assignee: Juneau Biosciences, LLC.
Inventors: Kenneth Ward, Rakesh N. Chettier, Hans Albertsen
Genetic Markers Associated with Endometriosis and Use Thereof
Publication number: 20100272713
Abstract: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.
Type: Application
Filed: April 22, 2010
Publication date: October 28, 2010
Applicant: JUNEAU BIOSCIENCES, LLC
Inventors: Kenneth Ward, Hans Albertsen
Genetic Markers Associated with Endometriosis and Use Thereof
Publication number: 20080305967
Abstract: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis.
Type: Application
Filed: March 27, 2008
Publication date: December 11, 2008
Applicant: JUNEAU BIOSCIENCES, LLC
Inventors: Kenneth Ward, Hans Albertsen
Method of Administering a Therapeutic
Publication number: 20080306034
Abstract: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a hormonal treatment such as a combined estrogen/progestin therapeutic which specifically includes an oral contraceptive that at least partially prevents or compensates for an endometriosis related symptom.
Type: Application
Filed: May 14, 2008
Publication date: December 11, 2008
Applicant: Juneau Biosciences, LLC
Inventor: Kenneth Ward
TM literally means unregistered trademark.
Trademark/IP law is extremely complex, but the jist is that TM (common law/unregistered) provides most of the protections and perception that full registration (R).
Primary reasons it has most likely not been registered:
1. No need, TM is sufficent. No direct competition, nor a likelihood that a competitor will also utilize the name.
2. Trademark previously registered, and while inactive, the name is still used. This Artguide event happens within the same region as Pred's artguide would be marketed/sold.
No concern.
Combination IMO. Consider one seller w/ 10 M shares.. would sell over time, likely 100-300k a day given they dont want the price to immediately crash. This would take a couple months minimum to clear out their position.
That level of relentless selling is more than enough to push us into a trend as we have seen.. remember a normal total volume day before the past 6 months was 100-300k shares traded.
But you bet MMs and technical retail are going to piggyback.
There is a net profit split agreement, as detailed under exclusive license in the form 10.